Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03914326 · ClinicalTrials.gov registry record · Phase 3
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,651
- Enrollment target
NCT03914326 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 9,651 participants.
The verdict
NCT03914326, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,651 participants
- Enrollment target
Study Summary
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes. The study will last for about 3.5-5 years. Participants will have up to 25 clinic visits and 1 phone call with the study doctor. Women cannot be in the study if pregnant, breast-feeding or if they plan to become pregnant during the study period.
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,651 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2024-08-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03914326
The ClinicalTrials.gov registry entry for NCT03914326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9,651 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT03914326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03914326 about?
NCT03914326 is a clinical study titled "A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes". The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet wit...
What is the current status of trial NCT03914326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,651 participants. The study started on 2019-06-17. Estimated completion is 2024-08-23.
What interventions are being tested in trial NCT03914326?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03914326?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.